The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...
Congress and the U.S. Food and Drug Administration (“FDA”) have sought to reform the accelerated approval process, an expedited development and approval pathway for drugs that provide ...
On January 6, the U.S. Food and Drug Administration (“FDA” or the “Agency”) released a draft guidance titled “Accelerated Approval and ...
The Office of Inspector General reviewed the FDA’s use of accelerated approval for 24 drugs, ultimately finding issues with ...
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...
The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...
The aducanumab approval raised concerns in Congress ... In light of this, the OIG examined the FDA's decision-making process in a sample of 24 accelerated drug approvals. Of the 24 drugs, three ...
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback